Parkinson's Disease Trial, Recruiting NCT06498349 Sponsor: University of Kiel Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT06498349
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 70 years or younger at the time of joining the trial
  • People who have been diagnosed with Parkinson's disease according to an established set of clinical diagnostic guidelines (called MDS criteria)
  • People whose first Parkinson's motor symptoms began at least 4 years ago
  • People who have moderate or severe problems with impulse control — such as compulsive gambling, hypersexuality, compulsive shopping, binge eating, obsessive hobbies, repetitive purposeless behaviours (called punding), or overuse of medication — based on specific scores on a recognised behaviour rating scale (called the Ardouin scale)
  • People whose Parkinson's motor symptoms improve by at least 30% when tested with a levodopa medication test, or who have a classic Parkinson's resting tremor
  • People who have already tried adjusting their medication to manage their symptoms
  • People who score 24 or higher on a standard memory and thinking test (called MoCA), measured while on their usual medication
  • People with a depression score below 20 on a standard scale (called BDI-II), measured while on medication; people with scores between 20 and 28 may still be considered, but only with careful review by a psychiatrist and willingness to follow that process
  • People who are able to understand what the study involves and what the treatment procedures require
  • People who have provided written consent before any study tests or procedures begin

Who may not be able to join:

  • People for whom brain surgery would be medically unsafe for any reason
  • People with severe ongoing depression (BDI-II score above 28)
  • People who have current thoughts of suicide (based on a specific question on the BDI-II scale)
  • People with dementia, indicated by a MoCA score below 24 while on their usual medication
  • People who have previously had brain surgery, brain tissue removal (ablation), or a device implanted inside the brain for any movement disorder
  • People who already have another active implanted medical device that could interfere with a brain stimulation (DBS) system
  • People currently participating in another clinical trial that targets or could interfere with impulse control disorders
  • People with a history of recurring seizures or a bleeding stroke
  • Women who are able to become pregnant and are not using adequate contraception
  • People with a serious illness that significantly reduces life expectancy, where brain stimulation surgery would not be appropriate under standard medical care
  • Women who are breastfeeding, or who are of childbearing potential and have a positive pregnancy test, or are not using adequate contraception
  • People with any condition that would prevent them from taking part in the study or completing study procedures
  • People with any significant health condition likely to interfere with study procedures or make it difficult to assess the study's results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ines Deboves, MD, University Hospital Bern, Inselspital, Department of Neurology

Phone: +49 (0)431 500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Kiel
Registry
ClinicalTrials.gov
Start date
5 September 2024
Est. completion
15 July 2027

Where this trial is recruiting

🇩🇪 Germany 🇳🇱 Netherlands 🇨🇭 Switzerland

Primary endpoints

Ardouin Scale of Behaviour in Parkinson's Disease (ASBPD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov